AIRLINK 69.90 Decreased By ▼ -3.16 (-4.33%)
BOP 4.93 Decreased By ▼ -0.16 (-3.14%)
CNERGY 4.29 Decreased By ▼ -0.08 (-1.83%)
DFML 31.20 Decreased By ▼ -1.25 (-3.85%)
DGKC 76.88 Increased By ▲ 1.39 (1.84%)
FCCL 19.82 Increased By ▲ 0.30 (1.54%)
FFBL 34.70 Decreased By ▼ -1.45 (-4.01%)
FFL 9.19 Decreased By ▼ -0.03 (-0.33%)
GGL 9.80 Decreased By ▼ -0.05 (-0.51%)
HBL 113.25 Decreased By ▼ -3.45 (-2.96%)
HUBC 133.00 Increased By ▲ 0.31 (0.23%)
HUMNL 6.96 Decreased By ▼ -0.14 (-1.97%)
KEL 4.24 Decreased By ▼ -0.17 (-3.85%)
KOSM 4.32 Decreased By ▼ -0.08 (-1.82%)
MLCF 36.55 Increased By ▲ 0.35 (0.97%)
OGDC 132.80 Decreased By ▼ -0.70 (-0.52%)
PAEL 22.40 Decreased By ▼ -0.20 (-0.88%)
PIAA 24.35 Decreased By ▼ -1.66 (-6.38%)
PIBTL 6.47 Decreased By ▼ -0.08 (-1.22%)
PPL 116.61 Increased By ▲ 1.30 (1.13%)
PRL 25.90 Decreased By ▼ -0.73 (-2.74%)
PTC 13.19 Decreased By ▼ -0.91 (-6.45%)
SEARL 52.21 Decreased By ▼ -1.24 (-2.32%)
SNGP 68.00 Increased By ▲ 0.75 (1.12%)
SSGC 10.57 Decreased By ▼ -0.13 (-1.21%)
TELE 8.30 Decreased By ▼ -0.12 (-1.43%)
TPLP 10.83 Increased By ▲ 0.08 (0.74%)
TRG 59.51 Decreased By ▼ -4.36 (-6.83%)
UNITY 25.12 No Change ▼ 0.00 (0%)
WTL 1.26 Decreased By ▼ -0.01 (-0.79%)
BR100 7,412 Decreased By -49.1 (-0.66%)
BR30 24,015 Decreased By -156.6 (-0.65%)
KSE100 70,782 Decreased By -321.1 (-0.45%)
KSE30 23,289 Decreased By -105.4 (-0.45%)

imagePARIS: Cancer cost the then 27 countries of the European Union 126 billion euros ($170.1 billion) in 2009, according to a study published on Monday.

The bill mainly comprised 51 billion euros in costs for health-scare systems, including drugs; 23 billion euros in unpaid care provided by friends and relatives of people with cancer; and 52 billion euros in lost productivity due to premature deaths and illness.

Britain, France, Germany and Italy accounted for most than two-thirds of the cost.

Four types of cancer -- breast, colorectal, lung and prostate -- contributed to around half of all new cancer diagnoses and deaths.

Lung cancer had the highest overall cost, of 18.8 billion euros, and was also responsible for the biggest loss of productivity.

The analysis should be useful for policymakers weighing decisions on where to allocate research funds, drugs and human resources, said researcher Ramon Luengo-Fernandez of the University of Oxford.

The study appears in The Lancet Oncology.

Comments

Comments are closed.